The civic record
Read. Follow. Verify.Arizona HB 4036 Restricts Compounded Weight-Loss Drugs and Imposes Sourcing and Testing Rules
Last action · February 18, 2026: FAILEDSponsor: Michele Peña
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
What This Bill Proposed
Arizona HB 4036 would prohibit the sale or distribution of compounded weight-loss medications—specifically those using GLP-1 or GIP receptor agonists—unless compounders and suppliers meet strict federal registration, quality testing, inspection, and record-keeping requirements. The bill establishes civil penalties of $1,000 per dose for violations, authorizes state board inspections, and bans deceptive advertising for compounded drugs.
The measure establishes new state-level oversight and $1,000-per-dose penalties for compounding pharmacies, wholesalers, and advertisers handling specific weight-loss and obesity medications, directly altering compliance obligations and supply-chain documentation rules in Arizona.
- Compounded medications are customized drugs created by pharmacists to meet specific patient needs when commercially available products are unsuitable or unavailable. context
- GLP-1 receptor agonist medications have experienced soaring demand for weight management, leading to increased federal and state scrutiny over the safety of compounded alternatives. context
Who It Would Have Affected
Groups the bill's text would have affected, as described in the record. Being affected is not a position for or against it.
Compounding Pharmacies
Compounding pharmacies must comply with strict bulk drug sourcing standards, conduct pre-use and finished batch testing, maintain records for two years post-expiration, and adhere to new advertising restrictions.
Drug Manufacturers and Wholesalers
Manufacturers and wholesalers selling bulk drug substances in Arizona for compounding must provide written verification of pharmaceutical-grade quality, testing documentation, and certificates of analysis.
State Board of Pharmacy
The Board is granted explicit authority to inspect compounding facilities, domestic suppliers, and wholesalers, request records, and adopt implementation rules.
Key Facts
You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.
Frequently Asked Questions
What types of drugs are targeted by the new restrictions in HB 4036?
What documentation must suppliers provide to compounding pharmacies?
What penalties can be applied for violating these compounding rules?
What else do you want to know?
News Coverage
Follow the record
Votes, people, money & the original sourceWhere This Stands
This bill did not become law - Failed in the House.
Procedural history
4 actions- Feb 18, 2026HouseFloorFAILED
- Feb 11, 2026HouseW/D
- Feb 10, 2026HouseFloorHouse Second Reading
- Feb 9, 2026HouseIntroducedHouse First Reading
Version history
Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.
View official text →Lobbying Activity
No state lobbying filings in our records match this bill. Federal lobbying reports (LDA) cover Congress, so they are not listed on state bills.
Full breakdown
Who this bill affects and the strongest case for and against it, written only from the bill’s own text.
Sponsors
Connected Entities
Sources
apps.azleg.gov
Analysis Score
0–100- Significance20Lowered because this bill did not pass (its text scored 75)
- Controversy65Intensity of disagreement among stakeholders
- Entertainment20Compellingness for a non-policy-wonk reader
- Buzz50Current news / social attention level
Publisher tools
